Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrclinonc.2015.53PMID 25824606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial

  2017cited by this paper
• ASCO Perspective : Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

  2016cited by this paper
• A meta-analysis of randomized controlled trials

  2016cited by this paper
• Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.

  2015cited by this paper
• Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

  2015cited by this paper
• Bladder Management With Epidural Anesthesia During Labor: A Randomized Controlled Trial

  2015cited by this paper
• Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

  2015cited by this paper
• Biomarkers: Exceptional responders—discovering predictive biomarkers

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma.

  2014cited by this paper
• Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

  2014cited by this paper
• Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

  2014cited by this paper
• Neoadjuvant Therapy and Vascular Resection During Pancreaticoduodenectomy: Shifting the Survival Curve for Patients with Locally Advanced Pancreatic Cancer

  2014cited by this paper
• BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study

  2014cited by this paper
• Testicular cancer and platinum: a double-edged sword.

  2014cited by this paper
• pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

  2014cited by this paper
• Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

  2014cited by this paper
• Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).

  2014cited by this paper
• Biomarker assessment from EUS-guided biopsy to predict outcomes and treatment in pancreatic cancer.

  2014cited by this paper
• A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).

  2014cited by this paper
• Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

  2014cited by this paper
• Is it better to transfer long-term cancer survivors to general practitioners or develop clinics for long-term survivors within the cancer centers?

  2014cited by this paper
• National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

  2014cited by this paper
• O-0003NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY

  2014cited by this paper
• Stromal response to Hedgehog signaling restrains pancreatic cancer progression

  2014cited by this paper
• Next-generation sequencing in pancreatic cancer: Revealing genomic mutations beyond KRAS.

  2014cited by this paper
• American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

  2014cited by this paper
• A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).

  2014cited by this paper
• Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.

  2014cited by this paper
• Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

  2014cited by this paper
• Mining the genomes of exceptional responders

  2014cited by this paper
• Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

  2014cited by this paper
• Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.

  2014cited by this paper
• A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

  2014cited by this paper
• Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

  2014cited by this paper
• The immune network in pancreatic cancer development and progression

  2014cited by this paper
• Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.

  2014cited by this paper
• Evidence for the Importance of Personalized Molecular Profiling in Pancreatic Cancer

  2014cited by this paper
• Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

  2013cited by this paper
• Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer

  2013cited by this paper
• A Single-Institution Experience

  2013cited by this paper
• Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

  2013cited by this paper
• Mutant KRAS is a druggable target for pancreatic cancer

  2013cited by this paper
• FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

  2013cited by this paper
• A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

  2013cited by this paper
• Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial.

  2013cited by this paper
• Clinical and molecular characterization of HER2 amplified-pancreatic cancer

  2013cited by this paper
• Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

  2013cited by this paper
• Molecular Pathways Molecular Pathways : JAK / STAT Pathway : Mutations , Inhibitors , and Resistance

  2013cited by this paper
• TH-302 plus gemcitabine (G+T) versus gemcitabine (G) in patients with previously untreated advanced pancreatic cancer (PAC).

  2013cited by this paper
• Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

  2013cited by this paper
• FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

  2013cited by this paper
• A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

  2013cited by this paper
• Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

  2013cited by this paper
• Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

  2013cited by this paper
• Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors

  2013cited by this paper
• US National Cancer Institute's new Ras project targets an old foe

  2013cited by this paper
• Pancreatic cancer.

  2013cited by this paper
• Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

  2013cited by this paper
• Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

  2013cited by this paper
• Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

  2013cited by this paper
• Featured Updates to the NCCN Guidelines

  2013cited by this paper
• Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

  2013cited by this paper
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

  2013cited by this paper
• Improvement of surgical results for pancreatic cancer.

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.

  2013cited by this paper
• Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial

  2013cited by this paper
• T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

  2013cited by this paper
• Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

  2012cited by this paper
• EMT and dissemination precede pancreatic tumor formation.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

  2012cited by this paper
• Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply

  2012cited by this paper
• A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

  2012cited by this paper
• Improved survival with MEK inhibition in BRAF-mutated melanoma.

  2012cited by this paper
• Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

  2012cited by this paper
• Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).

  2012cited by this paper
• Neoadjuvant/Preoperative Gemcitabine for Patients with Localized Pancreatic Cancer: A Meta-analysis of Prospective Studies

  2012cited by this paper
• Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators

  2012cited by this paper
• FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study

  2012cited by this paper
• BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.

  2012cited by this paper
• Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

  2012cited by this paper
• Genome Sequencing Identifies a Basis for Everolimus Sensitivity

  2012cited by this paper
• The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins

  2012cited by this paper
• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents.

  2012cited by this paper
• EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.

  2012cited by this paper
• Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer

  2012cited by this paper
• mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.

  2011cited by this paper
• Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.

  2011cited by this paper
• Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

  2011cited by this paper
• Otto Warburg's contributions to current concepts of cancer metabolism

  2011cited by this paper
• A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction

  2011cited by this paper
• Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

  2011cited by this paper

• A Comprehensive Review on the use of nanosecond pulsed electric fields in cancer therapy

  2026cites this paper
• CECT-Mamba: A Hierarchical Contrast-Enhanced-Aware Model for Pancreatic Tumor Subtyping from Multi-Phase CECT

  2025cites this paper
• Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: Clinical Utility, Trials, and Future Directions

  2025cites this paper
• Cannabidiol in pancreatic ductal adenocarcinoma: preclinical evidence, molecular mechanisms, and translational challenges

  2025cites this paper
• Natural Products Targeting the EGFR/HER2 Axis in Tumorigenesis: Interpretation of Molecular Mechanisms and Recent Insights Into Synergistic Strategies for Cancer Therapy

  2025cites this paper
• Cuproptosis-related gene CEP55 as a biomarker of pancreatic adenocarcinoma via multi-omics techniques and experimental validation

  2025cites this paper
• Pancreatic cancer in the era of precision medicine: challenges, advances, and the future of therapeutic strategies

  2025cites this paper
• Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer

  2025cites this paper
• Optogenetically Activatable MLKL as a Standalone Functional Module for Necroptosis and Therapeutic Applications in Antitumoral Immunity

  2025cites this paper
• A 3D Bioprinted Pancreatic Cancer Model Using Collagen-Gelatin Methacrylamide-Alginate Bioinks to Mimic the Desmoplastic Microenvironment

  2025cites this paper
• FOXM1‐Cx31 Axis Drives Pancreatic Cancer Stem Cell‐Like Properties and Chemoresistance

  2025cites this paper
• Warfarin and bevacizumab suppress tumor progression in pancreatic ductal adenocarcinoma by targeting EGFR-PI3K-Akt signaling: inhibition of proliferation/migration and apoptosis induction

  2025cites this paper
• The Possible Role of Immunotherapy in Locally Advanced Pancreatic Cancer Treatment

  2025influential citation
• TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis.

  2025cites this paper
• Innate Immunity‐Guided Macrophage‐Homing Nanoplatform for Oral Tumor Immunotherapy and Real‐Time Deep‐Tissue Imaging in Pre‐Clinical Models

  2025cites this paper
• Intracellular nanofiber formation triggers nuclear fragmentation to enhance chemotherapeutic effect of camptothecin

  2025cites this paper
• Patient-Derived 3D-Bioprinted models of pancreatic Cancer: Toward personalized therapy and overcoming tumor microenvironment challenges.

  2025cites this paper
• ERK2-mediated phosphorylation of ZEB1 at S322 enhances PD-L1 expression and EMT, leading to pancreatic cancer progression

  2025cites this paper
• Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/Smad2 pathway.

  2025cites this paper
• eEF2K is a poor prognostic factor and novel molecular target in pancreatic cancer: regulating tumor growth and progression via the tumor microenvironment

  2025cites this paper
• Predictors of futile surgery in upfront resectable pancreatic ductal adenocarcinoma. possible targets for neoadjuvant chemotherapy?

  2025cites this paper
• mRNA-Based Neoantigen Vaccines in Pancreatic Ductal Adenocarcinoma (PDAC)—A Promising Avenue in Cancer Immunotherapy

  2025cites this paper
• Diagnosis Approach For Head of Pancreatic Carcinoma with Hepatitis B

  2025cites this paper
• Oncogenic Peptide Encoded by Noncoding RNA of FOXM1 Promotes Pancreatic Cancer Malignancy Through PI3K/AKT Signaling

  2025cites this paper
• Hydrogel PCDME creates pancreatic cancer stem cells in OXPHOS metabolic state with TXNIP elevation.

  2025cites this paper
• WDR3 drives pancreatic cancer metastasis by enhancing TGF-α mRNA stability through YTHDC1.

  2025cites this paper
• A Polymer–Lipid Nanosystem Comprising siRNA and Gemcitabine for Pancreatic Cancer Treatment

  2025cites this paper
• Single-cell transcriptomics analysis reveals dynamic changes and prognostic signature in tumor microenvironment of PDAC

  2025cites this paper
• Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells

  2025cites this paper
• Advanced Detection of Pancreatic Cancer Circulating Tumor Cells Using Biomarkers and Magnetic Particle Spectroscopy

  2025cites this paper
• scKAN: interpretable single-cell analysis for cell-type-specific gene discovery and drug repurposing via Kolmogorov-Arnold networks

  2025cites this paper
• Self-expandable metal vs. plastic stents for preoperative biliary drainage in patients receiving neoadjuvant chemotherapy.

  2025cites this paper
• The multifaceted roles of deubiquitinating enzymes (DUBs) in pancreatic ductal adenocarcinoma

  2025influential citation
• Emerging targets in gastric and pancreatic cancer: Focus on Claudin 18.2.

  2024cites this paper
• miR-630 as a therapeutic target in pancreatic cancer stem cells: modulation of the PRKCI-Hedgehog signaling axis

  2024cites this paper
• Single-cell transcriptomics reveal the prognostic roles of epithelial and T cells and DNA methylation-based prognostic models in pancreatic cancer

  2024cites this paper
• Dual drug-loaded tumor-targeted polymeric nanoparticles for enhancing therapeutic response in pancreatic ductal adenocarcinoma

  2024cites this paper
• New Smoothened ligands based on the purine scaffold as potential agents for treating pancreatic cancer.

  2024cites this paper
• Anticancer effects of high-dose extracellular citrate treatment in pancreatic cancer cells under different glucose concentrations

  2024cites this paper
• Crocin-loaded zein beta-cyclodextrin nanoparticles: a promising strategy for inducing apoptosis in pancreatic cancer cells

  2024cites this paper
• Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives

  2024cites this paper
• Exosomal miR‐199a‐3p Secreted From Cancer‐Associated Adipocytes Promotes Pancreatic Cancer Progression

  2024cites this paper
• In silico profiling of the ADMET properties and inhibitory potentials of alkaloids against IFIT5 in renal cell carcinoma

  2024cites this paper
• Controllable Histotomy Based on Hierarchical Magnetic Microneedle Array Robots

  2024cites this paper
• Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer

  2024cites this paper
• Prognostic Value of Circulating Cell-Free DNA Concentration and Neutrophil-to-Lymphocyte Ratio in Patients with Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study

  2024cites this paper
• Targeting KRAS in pancreatic cancer

  2024cites this paper
• Bidirectional crosstalk between cancer cells and cancer‐associated fibroblasts in mixed organoid system elicits transcriptomic characteristics of pancreatic cancer with potential therapeutic vulnerabilities

  2024cites this paper
• Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight

  2024cites this paper
• Screening Metabolic Biomarkers in KRAS Mutated Mouse Acinar and Human Pancreatic Cancer Cells via Single-Cell Mass Spectrometry.

  2024cites this paper
• A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights

  2023cites this paper
• Phytochemicals in Pancreatic Cancer Treatment: A Machine Learning Study

  2023cites this paper
• PANoptosis-related long non-coding RNA signature to predict the prognosis and immune landscapes of pancreatic adenocarcinoma

  2023cites this paper
• Cells-in-Touch: 3D Printing in Reconstruction and Modelling of Microscopic Biological Geometries for Education and Future Research Applications

  2023cites this paper
• PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy

  2023cites this paper
• Effect of NFATc2- and Sp1-mediated TNFalpha Regulation on the Proliferation and Migration Behavior of Pancreatic Cancer Cells.

  2023cites this paper
• Exosomes as efficient platforms for delivering adenosine-tetra peptide conjugate to pancreatic cancer cells: An in vitro/in silico study

  2023cites this paper
• The genomic and evolutionary landscapes of anaplastic thyroid carcinoma

  2023cites this paper
• Silencing long noncoding RNA LINC01133 suppresses pancreatic cancer through regulation of microRNA‐1299‐dependent IGF2BP3

  2023cites this paper
• Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer.

  2023cites this paper
• Species-Deconvolved Proteomics for In Situ Investigation of Tumor-Stroma Interactions after Treatment of Pancreatic Cancer Patient-Derived Xenografts with Combined Gemcitabine and Paclitaxel.

  2023cites this paper
• miR-33a-3p regulates METTL3-mediated AREG stability and alters EMT to inhibit pancreatic cancer invasion and metastasis

  2023cites this paper
• Liposomal Nanostructures for Gemcitabine and Paclitaxel Delivery in Pancreatic Cancer.

  2023cites this paper
• Interventional Radiology in the Treatment of Pancreatic Adenocarcinoma: Present and Future Perspectives

  2023cites this paper
• A decision support system based on artificial intelligence and systems biology for the simulation of pancreatic cancer patient status

  2023influential citation
• New Insights into the Biological Response Triggered by Dextran-Coated Maghemite Nanoparticles in Pancreatic Cancer Cells and Their Potential for Theranostic Applications

  2023cites this paper
• Sono‐Activatable Semiconducting Polymer Nanoreshapers Multiply Remodel Tumor Microenvironment for Potent Immunotherapy of Orthotopic Pancreatic Cancer

  2023cites this paper
• Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21.

  2023cites this paper
• Neutralization of NET-associated human ARG1 enhances cancer immunotherapy

  2023cites this paper
• Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro

  2023cites this paper
• A novel anti-galectin-9 immunotherapy limits the early progression of pancreatic neoplastic lesions in transgenic mice

  2023cites this paper
• Linc00662 m6A promotes the progression and metastasis of pancreatic cancer by activating focal adhesion through the GTF2B-ITGA1-FAK pathway.

  2023cites this paper
• The bioengineered and multifunctional nanoparticles in pancreatic cancer therapy: Bioresponisive nanostructures, phototherapy and targeted drug delivery.

  2023cites this paper
• The application of single-cell sequencing in pancreatic neoplasm: analysis, diagnosis and treatment

  2022influential citation
• Marine-Inspired Drugs and Biomaterials in the Perspective of Pancreatic Cancer Therapies

  2022cites this paper
• Assessment of hypoxia-targeting therapy for gastrointestinal lymphoma in dogs: Preclinical test using murine models.

  2022cites this paper
• Liposomal co-delivery system encapsulating celastrol and paclitaxel displays highly enhanced efficiency and low toxicity against pancreatic cancer

  2022cites this paper
• A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma

  2022cites this paper
• Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer

  2022cites this paper
• Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis

  2022cites this paper
• Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma

  2022influential citation
• Overcoming Immunotherapeutic Resistance in PDAC: SIRPα-CD47 blockade.

  2022cites this paper
• The role of Jagged1 as a dynamic switch of cancer cell plasticity in PDAC assembloids

  2022cites this paper
• Quantitative proteomic analysis of oxaliplatin induced peripheral neurotoxicity.

  2022cites this paper
• Nuclear GSK-3β and Oncogenic KRas Lead to the Retention of Pancreatic Ductal Progenitor Cells Phenotypically Similar to Those Seen in IPMN

  2022cites this paper
• MUC16 Promotes Liver Metastasis of Pancreatic Ductal Adenocarcinoma by Upregulating NRP2 Associated Cell Adhesion.

  2022cites this paper
• Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations

  2022cites this paper
• Circulating Nucleic Acids as Novel Biomarkers for Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• Probe Synthesis Reveals Eukaryotic Translation Elongation Factor 1 Alpha 1 as the Anti-Pancreatic Cancer Target of BE-43547A2.

  2022cites this paper
• Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?

  2022cites this paper
• Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a systematic review and meta-analysis

  2022cites this paper
• Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a systematic review and meta-analysis.

  2022cites this paper
• Identification of genomic instability related lncRNA signature with prognostic value and its role in cancer immunotherapy in pancreatic cancer

  2022cites this paper
• The antitumor activity of hPRDX5 against pancreatic cancer and the possible mechanisms

  2022cites this paper
• Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.

  2022cites this paper
• Pancreatic cancer growth promoted by bone marrow mesenchymal stromal cell-derived IL-6 is reversed predominantly by IL-6 blockade.

  2022cites this paper
• Structure–Activity Relationship of Benzofuran Derivatives with Potential Anticancer Activity

  2022cites this paper
• CXCR4 expression in tumor associated cells in blood is prognostic for progression and survival in pancreatic cancer

  2022cites this paper
• The Effects of Analgesics on the Migration of Pancreatic Cancer Cells

  2022cites this paper
• Cascade Drug Delivery through Tumor Barriers of Pancreatic Cancer via Ultrasound in Combination with Functional Microbubbles.

  2022cites this paper